Expressão de HER2 em câncer gástrico: uma revisão sistemática
DOI:
https://doi.org/10.53660/CONJ-1672-2G14APalavras-chave:
Câncer de estômago; Expressão de ErbB2; Alvo terapêutico;Resumo
Introdução: o receptor HER2 é capaz de induzir proliferação e transformação celular nos tecidos tumorais. Estudos recentes avaliam o papel da proteína nos tumores gástricos e sua influência sobre a doença. Objetivo: sumarizar os conhecimentos que respondem à pergunta “qual a influência do aumento na expressão do receptor HER2 sobre o prognóstico dos pacientes com câncer gástrico?”. Método: revisão integrativa da literatura utilizando as bases de dados PubMed e Lilacs, com os descritores HER2, ErbB2, prognosis, survival, survival patients, stomach neoplasms, stomach cancers, gastric cancer. Resultados: A base de dados apresentou 249 artigos compatíveis com os filtros de pesquisa. Após pré-seleção e uma seleção mais criteriosa pelos autores, 36 artigos foram incluídos na amostra final. Conclusão: A relação entre HER2 superexpresso e o prognóstico para o câncer gástrico é divergente. Mas, evidenciou-se que, devido a diferentes mecanismos de interação HER2-Tumor, sua expressão no tecido tumoral pode auxiliar na decisão da conduta terapêutica.
Downloads
Referências
LI, Xuesong et al. Upregulation of circular RNA circ-ERBB2 predicts unfavorable prognosis and facilitates the progression of gastric cancer via miR-503/CACUL1 and miR-637/MMP-19 signaling. Biochemical and biophysical research communications, v. 511, n. 4, p. 926-930, 2019
AZNAB, Mozaffar et al. The role of human epidermal growth factor receptor (HER2/neu) in the prognosis of patients with gastric cancer. Asian Pacific journal of cancer prevention: APJCP, v. 20, n. 7, p. 1989, 2019
SUN, Li-Fei et al. The role of HER2 in self-renewal, invasion, and tumorigenicity of gastric cancer stem cells. Frontiers in oncology, v. 10, p. 1608, 2020
PARK, Ji Soo et al. The prognostic value of volume-based parameters using 18 F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer, v. 21, n. 2, p. 213-224, 2018
OZEN, Alaattin et al. The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Medical Oncology, v. 30, n. 1, p. 1-6, 2013
KIM, Jin Won et al. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer research, v. 32, n. 4, p. 1547-1553, 2012
LI, Guo-Cai et al. The expression of epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 based on tumor location affect survival in gastric cancer. Medicine, v. 99, n. 21, 2020
SHI, Hong-Zhi et al. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. World journal of gastroenterology, v. 23, n. 10, p. 1836, 2017
LI, Fang et al. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis. Pathology-Research and Practice, v. 217, p. 153280, 2021.
HE, Xiao Xiao et al. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. Journal of clinical pathology, v. 68, n. 5, p. 374-380, 2015
MOTOSHIMA, Shigenobu et al. Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget, v. 9, n. 10, p. 9262, 2018
JIMÉNEZ-FONSECA, Paula et al. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. Gastric Cancer, v. 20, n. 3, p. 465-474, 2017
KATAOKA, Yoshiki et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer, [S.L.], v. 16, n. 1, p. 84-93, 14 mar. 2012. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s10120-012-0150-9.
ANSARI, Jamshid et al. The prognostic significance of Her2-Neu over expression in gastric carcinomas. Iranian journal of cancer prevention, v. 4, n. 4, p. 170, 2011
PEREIRA, Marina Alessandra et al. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: her-2, microsatellite instability and pd-l1. Molecular Diagnosis & Therapy, [S.L.], v. 23, n. 6, p. 761-771, 8 out. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40291-019-00424-y.
UPRAK, Tevfik Kivilcim et al. HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters. Turkish Journal Of Surgery, [S.L.], v. 31, n. 4, p. 207-213, 8 dez. 2015. AVES Publishing Co.. http://dx.doi.org/10.5152/ucd.2015.2964.
OTSU, Hajime et al. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Research, Kavala, v. 4, n. 35, p. 2441-2446, abr. 2015.
ZHOU, Fei et al. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World Journal Of Surgical Oncology, [S.L.], v. 10, n. 1, p. 274, 2012. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/1477-7819-10-274.
FU, Jingwei et al. Human epidermal growth factor receptor 2 expressions and Janus-activated kinase/signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway may be associated with clinicopathological features and prognosis of gastric cancer. Journal Of Cancer Research And Therapeutics, [S.L.], v. 14, n. 9, p. 311, 2018. Medknow. http://dx.doi.org/10.4103/0973-1482.235348.
CHENG, Guoxiong et al. Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance. Open Life Sciences, [S.L.], v. 14, n. 1, p. 119-125, 13 maio 2019. Walter de Gruyter GmbH. http://dx.doi.org/10.1515/biol-2019-0013.
YUAN, C-L et al. Expression of SATB1 and HER2 in gastric cancer and its clinical significance. Eur Rev Med Pharmacol Sci ., [S.L.], v. 11, n. 20, p. 2256-2264, jun. 2016.
CAO, Guo-Dong et al. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. Bmc Cancer, [S.L.], v. 17, n. 1, p. 1-16, dez. 2017. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12885-017-3851-y.
FUSCO, Nicola et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Modern Pathology, [S.L.], v. 26, n. 6, p. 816-824, 25 jan. 2013. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/modpat hol.2012.228.
GENG, Yiting et al. Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients. Biomedicine & Pharmacotherapy, [S.L.], v. 66, n. 6, p. 419-424, set. 2012. Elsevier BV. http://dx.doi.org/10.1016/j.biopha.2012.03.002.
CHENG, Yu; ZHOU, Jin; LI, Honglun. Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer. Clinical And Translational Science, [S.L.], v. 8, n. 4, p. 320-325, 14 fev. 2015. Wiley. http://dx.doi.org/10.1111/cts.12263.
KUROKAWA, Yukinori et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer, [S.L.], v. 18, n. 4, p. 691-697, 16 set. 2014. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s10120-014-0430-7.
PEREIRA, Marina Alessandra et al. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: her-2, microsatellite instability and pd-l1. Molecular Diagnosis & Therapy, [S.L.], v. 23, n. 6, p. 761-771, 8 out. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40291-019-00424-y.
SHEN, Guo-Shuang et al. Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: a large-scale multicenter study in china. World Journal Of Gastroenterology, [S.L.], v. 22, n. 23, p. 5406, 2016. Baishideng Publishing Group Inc.. http://dx.doi.org/10.3748/wjg.v22.i23.5406.
SHENG, W.Q. et al. HER2 status in gastric cancers: a retrospective analysis from four chinese representative clinical centers and assessment of its prognostic significance. Annals Of Oncology, [S.L.], v. 24, n. 9, p. 2360-2364, set. 2013. Elsevier BV. http://dx.doi.org/10.1093/annonc/mdt232.
LAGO, N.M. et al. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience, v.14, p. 1020, jan. 2020. https://doi.org/10.3332/ecancer.2020.1020
JIANG, W. et al. High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surgical Oncology, v.14, n. 3, p. 220-225, set, 2015. https://doi.org/10.1016/j.suronc.2015.05.004
JUNIOR, P.N.A.; NETO, R.N.; FORONES, N.M. HER 2 expression as a prognostic factor in metastatic gastric cancer. Arquivos de gastroenterologia, v. 53, n. 2, p. 62-67, abr. 2016. https://doi.org/10.1590/S0004-28032016000200003
BAYRAK, M. et al. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clinical and Translational Oncology, v. 15, n.4, p; 307-312, abr. 2013. https://doi.org/10.1007/s12094-012-0921-0
LIU, W. et al. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. Journal of clinical gastroenterology, v. 46, n. 4, p. 31-37. abr. 2012. https://journals.lww.com/jcge/Abstract/2012/04000/HER_2_neu_Overexpression_is_an_Independent.3.aspx
JANJIGIAN, Y.Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Annals of Oncology, v. 23, n. 10, p. 2656-2662, out. 2012. https://doi.org/10.1093/annonc/mds104
SON, H.S. et al. Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection. Journal of gastric cancer, v. 14, n. 3, p. 180-186, set. 2014. https://doi.org/10.5230/jgc.2014.14.3.180
LORENZON, L. et al. Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? The Scientific World Journal, v. 2013, p. 196541, jan. 2013. https://doi.org/10.1155/2013/196541
WANG, Yang-Kun et al. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma. World Journal Of Gastroenterology, [S.L.], v. 21, n. 15, p. 4680-4687, 21 abr. 2015. Baishideng Publishing Group Inc.. http://dx.doi.org/10.3748/wjg.v21.i15.4680.
WANG, Yang-Kun et al. Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. Cancer Biomarkers, [S.L.], v. 21, n. 2, p. 439-447, 6 fev. 2018. IOS Press. http://dx.doi.org/10.3233/cbm-170671.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Conjecturas
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
